Synthesis of new pteridines as hypouricemic agents

Article abstract of DOI:10.1016/0223-5234(92)90144-P

A series of new pteridines and 3,4-dihydropteridines with substitution in position 2, showed a hypouricemic activity in rats. After a single oral administration in this species, the hypouricemic effect of 2-(methoxymethoxymethyl)-3,4-dihydropteridine maleate 26b and 2-(2,2,2-trifluoroethoxymethyl)-3,4-dihydropteridine maleate 32b is as potent as that of 1H-pyrazolo[3,4-d]pyrimidin-4-ol (allopurinol). We showed a long-lasting fall of uricemia in further investigation of compound 26b; this fall can reach 80%. Compound 26b, unlike allopurinol, is not an in vitro xanthine oxidase inhibitor, but the ex vivo inhibition could be proved. It could be useful in the treatment of fout in human beings.